GSK to launch Paxil CR in July

Published: 2004-07-01 06:57:00

Updated: 2004-07-01 06:57:00

GSK unveiled its plan to launch Paxil (paroxetine HCl) controlled release tablet (12.5 mg) in July, which belongs to a class of the selective serotonin reuptake inhibitors (SSRIs) having broad range of efficacy in mood and anxiety disorders, including major depressive disorders, panic disorder, g...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK